Skip to main content
Premium Trial:

Request an Annual Quote

CellChorus Receives $2.2M SBIR Grant From NIGMS

NEW YORK – CellChorus, a Houston-based cell analysis firm, said on Wednesday that it has received a $2.2 million Small Business Innovation Research (SBIR) Fast-Track grant.

The funding from the National Institute of General Medical Sciences will support development of the firm's Time-Lapse Imaging Microscopy in Nanowell Grids (TIMING) platform for analysis of cell-cell interactions at the single-cell level.

The fast-track process allows applicants to submit both Phase I and Phase II applications at once, which can minimize the funding gap between phases. A $1.9 million Phase II grant will kick in after CellChorus reaches milestones under its $324,000 Phase I grant.

CellChorus, a University of Houston spinout, launched in 2019 and offers access to its platform though a commercial service.

The TIMING platform helps quantify "how immune cells move, interact, kill, survive, and secrete biomolecules at single-cell resolution," the firm said in a statement. "Data and insights from the TIMING platform enable the field to develop, manufacture, and deliver novel therapies faster, at less expense, and with higher rates of success to benefit patients in oncology, infectious diseases, and a wide range of other diseases and disorders."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.